Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05904886




Registration number
NCT05904886
Ethics application status
Date submitted
23/05/2023
Date registered
15/06/2023
Date last updated
18/11/2024

Titles & IDs
Public title
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
Scientific title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Secondary ID [1] 0 0
2023-503422-39-00
Secondary ID [2] 0 0
CO44668
Universal Trial Number (UTN)
Trial acronym
SKYSCRAPER-14
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Hepatocellular 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Bevacizumab
Treatment: Drugs - Tiragolumab
Other interventions - Placebo

Experimental: Atezolizumab + Bevacizumab + Tiragolumab - Atezolizumab plus bevacizumab plus tiragolumab will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Placebo comparator: Atezolizumab + Bevacizumab + Placebo - Atezolizumab, bevacizumab plus placebo will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.


Treatment: Drugs: Atezolizumab
Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

Treatment: Drugs: Bevacizumab
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Treatment: Drugs: Tiragolumab
Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.

Other interventions: Placebo
Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Investigator-Assessed Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Timepoint [1] 0 0
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)
Primary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
From randomization to death from any cause (up to approximately 36 months)
Secondary outcome [1] 0 0
Investigator-Assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1
Timepoint [1] 0 0
From randomization up to approximately 36 months
Secondary outcome [2] 0 0
Investigator-Assessed Duration of Objective Response (DOR) According to RECIST v1.1
Timepoint [2] 0 0
From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)
Secondary outcome [3] 0 0
Investigator-Assessed PFS Rate According to RECIST v1.1 at 6 and 12 Months
Timepoint [3] 0 0
Month 6, Month 12
Secondary outcome [4] 0 0
OS Rate at 1 and 2 Years
Timepoint [4] 0 0
Year 1, Year 2
Secondary outcome [5] 0 0
Investigator-Assessed PFS According to Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST)
Timepoint [5] 0 0
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)
Secondary outcome [6] 0 0
Investigator-Assessed Confirmed ORR According to HCC mRECIST
Timepoint [6] 0 0
From randomization up to approximately 36 months
Secondary outcome [7] 0 0
Investigator-Assessed DOR According to HCC mRECIST
Timepoint [7] 0 0
From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 36 months)
Secondary outcome [8] 0 0
Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer 30 (QLQ-C30) Subscales
Timepoint [8] 0 0
From randomization up to approximately 36 months
Secondary outcome [9] 0 0
Change from Baseline in GHS/QoL, Physical Functioning, and Role Functioning Assessed Using the EORTC QLQ-C30
Timepoint [9] 0 0
From baseline up to approximately 36 months
Secondary outcome [10] 0 0
Percentage of Participants With Adverse Events
Timepoint [10] 0 0
Up to approximately 36 months
Secondary outcome [11] 0 0
Serum Concentrations of Atezolizumab
Timepoint [11] 0 0
Prior to the first infusion and 30 minutes after atezolizumab infusion on Day 1 of Cycle 1 (cycle = 21 days), prior to infusion on Day 1 of Cycles 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)
Secondary outcome [12] 0 0
Serum Concentrations of Tiragolumab
Timepoint [12] 0 0
Prior to the first infusion and 30 minutes after tiragolumab infusion on Day 1 of Cycle 1 (cycle = 21 days), prior to infusion on Day 1 of Cycles 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)
Secondary outcome [13] 0 0
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab
Timepoint [13] 0 0
Prior to the first infusion on Day 1 of Cycles (cycle = 21 days) 1, 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)
Secondary outcome [14] 0 0
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Timepoint [14] 0 0
Prior to the first infusion on Day 1 of Cycles (cycle = 21 days) 1, 2, 3, 4, 8, 12, 16 and at treatment discontinuation visit (up to approximately 36 months)

Eligibility
Key inclusion criteria
* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
* Disease that is not amenable to curative surgical and/or locoregional therapies
* No prior systemic treatment for locally advanced or metastatic and/or unresectable HCC
* Measurable disease according to RECIST v1.1
* ECOG Performance Status of 0 or 1 within 7 days prior to randomization
* Child-Pugh Class A within 7 days prior to randomization
* Adequate hematologic and end-organ function
* Female participants of childbearing potential must be willing to avoid pregnancy within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo
* Male participants with a female partner of childbearing potential or pregnant female partner must remain abstinent or use a condom during the treatment period and for 6 months after the final dose of bevacizumab and for 90 days after the final dose of tiragolumab/placebo to avoid exposing the embryo.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnancy or breastfeeding within 5 months after the final dose of atezolizumab, within 6 months after the final dose of bevacizumab, and within 90 days after the final dose of tiragolumab/placebo
* Prior treatment with CD137 agonists or immune checkpoint blockade therapies
* Treatment with investigational therapy within 28 days prior to initiation of study treatment
* Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
* Treatment with systemic immunostimulatory agents
* Treatment with systemic immunosuppressive medication
* Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
* A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
* Active or history of autoimmune disease or immune deficiency
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
* History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
* Mixed histology or other subtypes/variants of HCC, including, but not limited to, known liver adenocarcinoma, fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
* Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
* Acute Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection
* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/09/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2026
Actual
Sample size
Target
650
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nevada
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Belgium
State/province [25] 0 0
Bonheiden
Country [26] 0 0
Belgium
State/province [26] 0 0
Bruxelles
Country [27] 0 0
Belgium
State/province [27] 0 0
Edegem
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Belgium
State/province [29] 0 0
Roeselare
Country [30] 0 0
Brazil
State/province [30] 0 0
ES
Country [31] 0 0
Brazil
State/province [31] 0 0
MG
Country [32] 0 0
Brazil
State/province [32] 0 0
PE
Country [33] 0 0
Brazil
State/province [33] 0 0
RJ
Country [34] 0 0
Brazil
State/province [34] 0 0
RO
Country [35] 0 0
Brazil
State/province [35] 0 0
RS
Country [36] 0 0
Brazil
State/province [36] 0 0
SP
Country [37] 0 0
Canada
State/province [37] 0 0
Alberta
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
China
State/province [40] 0 0
Baoji City
Country [41] 0 0
China
State/province [41] 0 0
Beijing City
Country [42] 0 0
China
State/province [42] 0 0
Beijing
Country [43] 0 0
China
State/province [43] 0 0
Changchun City
Country [44] 0 0
China
State/province [44] 0 0
Changsha CITY
Country [45] 0 0
China
State/province [45] 0 0
Changsha
Country [46] 0 0
China
State/province [46] 0 0
Chengdu City
Country [47] 0 0
China
State/province [47] 0 0
Fuzhou City
Country [48] 0 0
China
State/province [48] 0 0
Guangzhou City
Country [49] 0 0
China
State/province [49] 0 0
Guangzhou
Country [50] 0 0
China
State/province [50] 0 0
Hangzhou
Country [51] 0 0
China
State/province [51] 0 0
Harbin
Country [52] 0 0
China
State/province [52] 0 0
Hefei
Country [53] 0 0
China
State/province [53] 0 0
Jinan
Country [54] 0 0
China
State/province [54] 0 0
Lishui City
Country [55] 0 0
China
State/province [55] 0 0
Nanning City
Country [56] 0 0
China
State/province [56] 0 0
Nanning
Country [57] 0 0
China
State/province [57] 0 0
Shanghai City
Country [58] 0 0
China
State/province [58] 0 0
ShenYang
Country [59] 0 0
China
State/province [59] 0 0
Tianjin
Country [60] 0 0
China
State/province [60] 0 0
Wuhan City
Country [61] 0 0
China
State/province [61] 0 0
Xi'an
Country [62] 0 0
Côte D'Ivoire
State/province [62] 0 0
Abidjan
Country [63] 0 0
France
State/province [63] 0 0
Caen Cedex
Country [64] 0 0
France
State/province [64] 0 0
La Tronche
Country [65] 0 0
France
State/province [65] 0 0
Lille
Country [66] 0 0
France
State/province [66] 0 0
Limoges
Country [67] 0 0
France
State/province [67] 0 0
Marseille
Country [68] 0 0
France
State/province [68] 0 0
Montpellier
Country [69] 0 0
France
State/province [69] 0 0
Nantes
Country [70] 0 0
France
State/province [70] 0 0
Paris
Country [71] 0 0
France
State/province [71] 0 0
Reims
Country [72] 0 0
France
State/province [72] 0 0
Valence
Country [73] 0 0
France
State/province [73] 0 0
Vandoeuvre-les-nancy
Country [74] 0 0
France
State/province [74] 0 0
Villejuif
Country [75] 0 0
Germany
State/province [75] 0 0
Esslingen
Country [76] 0 0
Germany
State/province [76] 0 0
Göttingen
Country [77] 0 0
Germany
State/province [77] 0 0
Lübeck
Country [78] 0 0
Germany
State/province [78] 0 0
Mageburg
Country [79] 0 0
Germany
State/province [79] 0 0
Mainz
Country [80] 0 0
Germany
State/province [80] 0 0
Tübingen
Country [81] 0 0
Germany
State/province [81] 0 0
Ulm
Country [82] 0 0
Hong Kong
State/province [82] 0 0
Hong Kong
Country [83] 0 0
Hong Kong
State/province [83] 0 0
Shatin
Country [84] 0 0
Italy
State/province [84] 0 0
Campania
Country [85] 0 0
Italy
State/province [85] 0 0
Emilia-Romagna
Country [86] 0 0
Italy
State/province [86] 0 0
Lazio
Country [87] 0 0
Italy
State/province [87] 0 0
Liguria
Country [88] 0 0
Italy
State/province [88] 0 0
Lombardia
Country [89] 0 0
Italy
State/province [89] 0 0
Puglia
Country [90] 0 0
Italy
State/province [90] 0 0
Sicilia
Country [91] 0 0
Italy
State/province [91] 0 0
Veneto
Country [92] 0 0
Japan
State/province [92] 0 0
Aichi
Country [93] 0 0
Japan
State/province [93] 0 0
Chiba
Country [94] 0 0
Japan
State/province [94] 0 0
Ehime
Country [95] 0 0
Japan
State/province [95] 0 0
Fukuoka
Country [96] 0 0
Japan
State/province [96] 0 0
Hiroshima
Country [97] 0 0
Japan
State/province [97] 0 0
Hokkaido
Country [98] 0 0
Japan
State/province [98] 0 0
Hyogo
Country [99] 0 0
Japan
State/province [99] 0 0
Ishikawa
Country [100] 0 0
Japan
State/province [100] 0 0
Iwate
Country [101] 0 0
Japan
State/province [101] 0 0
Kanagawa
Country [102] 0 0
Japan
State/province [102] 0 0
Kyoto
Country [103] 0 0
Japan
State/province [103] 0 0
Osaka
Country [104] 0 0
Japan
State/province [104] 0 0
Tochigi
Country [105] 0 0
Japan
State/province [105] 0 0
Tokyo
Country [106] 0 0
Kenya
State/province [106] 0 0
Nairobi
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Goyang-si
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Gyeonggi-do
Country [109] 0 0
Korea, Republic of
State/province [109] 0 0
Jeollanam-do
Country [110] 0 0
Korea, Republic of
State/province [110] 0 0
Seoul
Country [111] 0 0
Korea, Republic of
State/province [111] 0 0
Ulsan
Country [112] 0 0
Mexico
State/province [112] 0 0
Mexico CITY (federal District)
Country [113] 0 0
Mexico
State/province [113] 0 0
Nuevo LEON
Country [114] 0 0
Mexico
State/province [114] 0 0
Oaxaca
Country [115] 0 0
Morocco
State/province [115] 0 0
Casablanca
Country [116] 0 0
Morocco
State/province [116] 0 0
FES
Country [117] 0 0
Morocco
State/province [117] 0 0
Marrakech
Country [118] 0 0
Morocco
State/province [118] 0 0
Rabat
Country [119] 0 0
New Zealand
State/province [119] 0 0
Auckland
Country [120] 0 0
New Zealand
State/province [120] 0 0
Christchurch
Country [121] 0 0
New Zealand
State/province [121] 0 0
Wellington
Country [122] 0 0
Nigeria
State/province [122] 0 0
JOS
Country [123] 0 0
Nigeria
State/province [123] 0 0
Lagos
Country [124] 0 0
Poland
State/province [124] 0 0
Gdansk
Country [125] 0 0
Poland
State/province [125] 0 0
Kraków
Country [126] 0 0
Poland
State/province [126] 0 0
Myslowice
Country [127] 0 0
Poland
State/province [127] 0 0
Warszawa
Country [128] 0 0
Puerto Rico
State/province [128] 0 0
San Juan
Country [129] 0 0
Singapore
State/province [129] 0 0
Singapore
Country [130] 0 0
South Africa
State/province [130] 0 0
Johannesburg
Country [131] 0 0
South Africa
State/province [131] 0 0
Polokwane
Country [132] 0 0
South Africa
State/province [132] 0 0
Pretoria
Country [133] 0 0
Spain
State/province [133] 0 0
Asturias
Country [134] 0 0
Spain
State/province [134] 0 0
Navarra
Country [135] 0 0
Spain
State/province [135] 0 0
Barcelona
Country [136] 0 0
Spain
State/province [136] 0 0
Burgos
Country [137] 0 0
Spain
State/province [137] 0 0
Jaen
Country [138] 0 0
Spain
State/province [138] 0 0
Madrid
Country [139] 0 0
Spain
State/province [139] 0 0
Valencia
Country [140] 0 0
Taiwan
State/province [140] 0 0
Taichung
Country [141] 0 0
Taiwan
State/province [141] 0 0
Tainan
Country [142] 0 0
Taiwan
State/province [142] 0 0
Taipei
Country [143] 0 0
Taiwan
State/province [143] 0 0
Taoyuan
Country [144] 0 0
Thailand
State/province [144] 0 0
Bangkok
Country [145] 0 0
Thailand
State/province [145] 0 0
ChiangMai
Country [146] 0 0
Thailand
State/province [146] 0 0
Khon Kaen
Country [147] 0 0
Turkey
State/province [147] 0 0
Adana
Country [148] 0 0
Turkey
State/province [148] 0 0
Ankara
Country [149] 0 0
Turkey
State/province [149] 0 0
Diyarbakir
Country [150] 0 0
Turkey
State/province [150] 0 0
Edirne
Country [151] 0 0
Turkey
State/province [151] 0 0
Kar?iyaka
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Edinburgh
Country [153] 0 0
United Kingdom
State/province [153] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Chugai Pharmaceutical
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
Trial website
https://clinicaltrials.gov/study/NCT05904886
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number: CO44668 https://forpatients.roche.com/
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S. Only)
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05904886